ALX Oncology Enhances Board with Expert Appointment, Meets Nasdaq Standards
Company Announcements

ALX Oncology Enhances Board with Expert Appointment, Meets Nasdaq Standards

ALX Oncology Holdings (ALXO) has shared an announcement.

ALX Oncology Holdings Inc. boosted its board’s expertise by appointing Dr. Alan Sandler as a Class III director, with a term ending in 2026. Dr. Sandler, with a rich background in oncology including executive roles at Mirati Therapeutics and Genentech, and academic positions at prestigious universities, is set to contribute to the Audit and Compensation Committees. His experience deemed him independent according to SEC and Nasdaq standards, allowing the company to meet Nasdaq’s requirement for a majority of independent directors. The board’s size was adjusted to six following the resignations of Drs. Pons and Randolph, who remain in senior company positions.

For detailed information about ALXO stock, go to TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskALX Oncology Highlights Promising Trial Results
TipRanks Auto-Generated NewsdeskALX Oncology Reports Clinical Progress and Financial Stability
TheFlyALX Oncology reports Q3 EPS (58c) consensus (78c)
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App